- Oops!Something went wrong.Please try again later.
Dr. Avindra Nath, Clinical Director of National Institute of Neurological Disorders and Stroke (NINDS), presented novel pre-clinical results of the Amyotrophic lateral sclerosis (ALS) research program developed in partnership with GeNeuro
confirm that HERV-K ENV is present in the cerebro-spinal fluid of sporadic ALS patients;
elucidate the pathogenic effect of HERV-K ENV on motor neurons; and
show in preclinical models the therapeutic potential of GeNeuro’s specific anti-HERV-K ENV antibody.
GENEVA, Switzerland, October 18, 2021--(BUSINESS WIRE)--Regulatory News:
GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that the NINDS, part of the U.S. National Institutes of Health (NIH), presented novel pre-clinical results at the American Neurological Association (ANA) annual meeting, October 17-19, confirming in pre-clinical models of ALS the neurotoxic properties of HERV-K ENV, a retroviral envelope protein encoded by a pathogenic member of the HERV-K family of endogenous human retroviruses, and the therapeutic potential of GeNeuro's antibody developed to neutralize HERV-K ENV.
"Our pre-clinical work on ALS has evidenced that HERV-K ENV mediates toxicity via three interlinked pathways, leading to neuronal cell death. GeNeuro’s GN-K01 antibody has demonstrated to neutralize this effect in pre-clinical in vivo and in vitro models," said Dr. Avindra Nath, clinical director at the National Institute of Neurological Disorders and Stroke. "This novel preclinical data holds promises that neutralizing HERV-K ENV with GeNeuro’s antibody could become a treatment option for patients with sporadic ALS".
"GeNeuro continues its mission to leverage its expertise in HERV biology to bring potential new treatments to patients, particularly in areas of high medical needs such as ALS. We are fortunate and proud to work with the NINDS team led by Dr. Avindra Nath to develop a new approach targeting HERV-K ENV," said Hervé Perron, Chief Scientific Officer at GeNeuro.
Following the extension of the partnership with the NINDS announced at the end of 2018, GeNeuro had launched a preclinical development program for its anti-HERV-K ENV antibody, which is now humanized and ready to enter GMP manufacturing. The program could start clinical trials as early as 2022.
"These results confirm the potentially key role of HERV-K ENV in ALS and the potential of GeNeuro’s new antibody in this indication," said Jesús Martin-Garcia, CEO of GeNeuro. "We will now seek partnerships to bring this product to patients as rapidly as possible."
Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease or clinically as motor neuron disease, is a fatal, rapidly progressive neurodegenerative disease characterized by loss of motor neurons leading to progressive muscular paralysis. The incidence of ALS is approximately 5 per 100,000 individuals in the USA, 1-3 per 100,000 individuals worldwide, and is consistent across diverse populations.
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It owns rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211017005051/en/
Chairman and CEO
+41 22 552 4800
Louis-Victor Delouvrier / Mathilde Bohin (investors)
+33 1 44 71 98 52
Arthur Rouillé (media)
+33 1 44 71 94 98